Article in Nanoscale horizons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Boaz Y BishopDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. pinelopi.kapitsinou@northwestern.edu.
Swagat H SharmaDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA. evan.scott@virginia.edu.
Ratnakar TiwariDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. pinelopi.kapitsinou@northwestern.edu.
Simseok A YukDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA. evan.scott@virginia.edu.ORCID http://orcid.org/0000-0002-6610-4940
Sultan AlmunifDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA. evan.scott@virginia.edu.
Susan E QuagginDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. pinelopi.kapitsinou@northwestern.edu.
Evan A ScottDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA. evan.scott@virginia.edu.ORCID http://orcid.org/0000-0002-8945-2892
Pinelopi P KapitsinouDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. pinelopi.kapitsinou@northwestern.edu.ORCID http://orcid.org/0000-0002-6953-0988
Funding
Macrophages and attenuation of inflammation resolution in APOL1 nephropathyR01DK131521 · NIDDK · NORTHWESTERN UNIVERSITY · 2022 to 2025
$1.1M
Resource Development CoreU54DK137516 · NORTHWESTERN UNIVERSITY · 2025 to 2025
$957k
Endothelial PHD2/HIF Axis in Ischemic Kidney Injury and InflammationR01DK115850 · NIDDK · NORTHWESTERN UNIVERSITY · 2022 to 2025
$910k
Physical Activity/Physical Function and Longitudinal Changes in Cognitive Function in Adults with Chronic Kidney Disease.TL1DK132769 · NORTHWESTERN UNIVERSITY · 2025 to 2025
While nanomedicine holds great promise for kidney disease, targeted delivery remains a major challenge. Most nanocarriers rely on passive accumulation or epithelial-specific ligands, limiting their utility in complex, inflamed renal environments. In acute kidney injury (AKI), inflammation and vascular dysfunction play central roles, yet targeting strategies beyond the tubule remain underexplored. Here, dual-ligand micelles are developed to enhance nanocarrier localization to the inflamed kidney by simultaneously engaging both organ- and injury-specific cues. Poly(ethylene glycol)-
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Enabling organ- and injury-specific nanocarrier targeting · full record | Socratic